FDA Grants Extended Breakthrough Therapy Designation to NS-089/NCNP-02 for Duchenne Muscular Dystrophy
NS Pharma's recent announcement highlights the regulatory acknowledgment by the U.S. Food and Drug Administration, underscoring the significance of their investigational candidate, NS089/NCNP-02. This designation is intended for patients who have Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
The foundation for this Breakthrough Therapy Designation is established upon the outcomes of a clinical trial initiated by investigators and carried out in Japan. The FDA grants this designation to facilitate the development and review of drugs aimed at treating serious or life-threatening diseases. To qualify, there must be initial clinical evidence suggesting that the drug could offer significant improvements over current therapies, with clinically meaningful endpoints.
NS-089/NCNP-02 is an antisense nucleotide that originated from collaborative research involving NS Pharma's parent company, Nippon Shinyaku, and the National Center of Neurology and Psychiatry. The development plan for NS-089/NCNP-02 includes a Phase 2 study to be conducted by NS Pharma in the United States and another Phase 2 study led by Nippon Shinyaku in Japan.
Duchenne Muscular Dystrophy (Duchenne) is a progressive type of muscular dystrophy primarily affecting males. It leads to progressive weakness and loss of skeletal, cardiac, and respiratory muscles. Early signs of Duchenne may involve delays in achieving motor milestones like sitting, standing, or walking. Over time, mobility declines, often requiring the use of a wheelchair during adolescence. Cardiac and respiratory issues typically arise during the teenage years and can result in severe and life-threatening complications.
